Erectile dysfunction affects approximately 150 million men worldwide — a number projected to reach 322 million by 2025 — making it one of the most prevalent yet under-discussed chronic conditions affecting quality of life [1]. Far more than a psychological or lifestyle inconvenience, ED is increasingly recognized as a sentinel biomarker of systemic vascular disease: the penile vasculature, with its small-diameter arteries (1–2 mm) and high endothelial surface-area-to-volume ratio, is among the first vascular beds to manifest the functional consequences of endothelial dysfunction, atherosclerosis, and microvascular damage [2].

Where conventional therapies fall short. PDE5 inhibitors (sildenafil, tadalafil) revolutionized ED management, yet 30–50% of men with ED do not respond adequately to oral pharmacotherapy — particularly those with diabetes, severe vasculopathy, or post-radical prostatectomy neurovascular injury [3]. Intracavernosal injections, vacuum devices, and penile implants offer alternatives but address the symptom — impaired erectile hemodynamics — without repairing the underlying tissue pathology. None of these approaches regenerates the cavernosal smooth muscle, restores the nitric oxide–cGMP signaling axis, or reverses the fibrotic remodeling that characterizes advanced ED.

The deeper problem is tissue-level. At the histological level, ED is characterized by progressive loss of cavernosal smooth muscle cells, accumulation of collagen within the corpus cavernosum (fibrosis), apoptosis of endothelial cells lining the cavernosal sinusoids, and degeneration of the cavernosal nerves (particularly the nitrergic fibers that mediate nitric oxide release during erection). These structural changes — collectively termed cavernosal veno-occlusive dysfunction — render the penis incapable of trapping blood during erection regardless of how much arterial inflow is achieved pharmacologically [4].

MSC therapy targets the root cause. Rather than temporarily augmenting the nitric oxide signal as PDE5 inhibitors do, mesenchymal stem cells address the structural deficit directly: they engraft in damaged cavernosal tissue, secrete angiogenic factors (VEGF, bFGF, HGF) that stimulate new blood vessel formation, release neurotrophic factors (BDNF, NGF, GDNF) that promote cavernosal nerve regeneration, differentiate toward smooth muscle and endothelial lineages, and reduce fibrosis through paracrine modulation of TGF-β/Smad signaling [5]. This multi-mechanism regenerative approach is what distinguishes MSC therapy from all currently approved ED treatments.

How MSCs Target the Pathophysiology of Erectile Dysfunction

MSCs address ED through several interconnected mechanisms, each supported by a substantial body of preclinical evidence spanning over two decades of research:

1. Endothelial repair and angiogenesis. The penile endothelium is exquisitely sensitive to damage from hyperglycemia, oxidative stress, and shear-stress dysfunction — all hallmarks of the metabolic syndrome that underlies most cases of ED. MSCs secrete a rich cocktail of pro-angiogenic factors — VEGF, basic fibroblast growth factor (bFGF), hepatocyte growth factor (HGF), angiopoietin-1, and platelet-derived growth factor (PDGF) — that collectively stimulate endothelial progenitor cell recruitment, endothelial tube formation, and microvascular network expansion within the corpus cavernosum [6]. In a rat model of diabetic ED, intracavernosal injection of bone marrow-derived MSCs increased cavernosal endothelial content by approximately 2.1-fold and capillary density by approximately 1.8-fold relative to untreated diabetic controls at 4 weeks post-treatment.

2. Smooth muscle preservation and anti-fibrotic remodeling. The corpus cavernosum is predominantly smooth muscle, and the ratio of smooth muscle to collagen is the single most important histological predictor of erectile function. MSCs suppress the TGF-β1/Smad2/3 fibrotic signaling pathway — which drives fibroblast-to-myofibroblast transition and pathological collagen deposition — while simultaneously promoting the survival and proliferation of existing cavernosal smooth muscle cells through HGF and IGF-1 secretion [7]. In the streptozotocin-induced diabetic rat model, MSC-treated animals preserved a smooth-muscle-to-collagen ratio of approximately 0.38 (vs. 0.21 in untreated diabetic rats and 0.44 in non-diabetic controls), with corresponding improvements in intracavernosal pressure responses to cavernosal nerve stimulation.

3. Cavernosal nerve regeneration. Neurogenic ED — resulting from damage to the cavernosal nerves during radical prostatectomy, pelvic surgery, or radiation — is among the most treatment-resistant forms of ED. MSCs secrete neurotrophic factors including brain-derived neurotrophic factor (BDNF), nerve growth factor (NGF), glial cell line-derived neurotrophic factor (GDNF), and neurotrophin-3 (NT-3), which promote axonal sprouting, Schwann cell migration, and re-myelination of damaged cavernosal nerve fibers [8]. In the rat bilateral cavernosal nerve crush model (the standard preclinical model of post-prostatectomy ED), intracavernosal MSC injection increased the number of neuronal nitric oxide synthase (nNOS)-positive nerve fibers by approximately 2.5-fold and preserved nitrergic nerve-mediated erectile responses at levels approaching those of sham-operated controls.

4. Immunomodulation of chronic inflammation. Chronic low-grade inflammation — driven by obesity, diabetes, and metabolic syndrome — creates a hostile microenvironment within the corpus cavernosum characterized by elevated TNF-α, IL-6, and M1-polarized macrophages. MSCs shift macrophages from the pro-inflammatory M1 phenotype to the anti-inflammatory, pro-regenerative M2 phenotype, reduce local levels of TNF-α and IL-6, and increase IL-10 and TGF-β production [9]. This immunomodulation is not merely anti-inflammatory — it actively promotes tissue repair by creating a permissive environment for angiogenesis, neurogenesis, and myogenesis.

5. Restoration of the nitric oxide–cGMP signaling axis. The canonical pathway of erection — nitric oxide release from nitrergic nerves and endothelial cells → activation of soluble guanylyl cyclase → cGMP production → smooth muscle relaxation — is impaired at multiple points in ED. MSCs restore endothelial nitric oxide synthase (eNOS) expression in cavernosal endothelial cells, increase nNOS expression in regenerating nerve fibers, and upregulate the expression of soluble guanylyl cyclase and protein kinase G in cavernosal smooth muscle [10]. This multi-level restoration of the NO–cGMP axis may partly explain why MSC therapy has been shown to restore responsiveness to PDE5 inhibitors in previously PDE5i-non-responsive animal models.

Preclinical Evidence: Two Decades of Animal Model Data

The preclinical evidence for MSC therapy in ED is among the most extensive in regenerative medicine, spanning over 20 years and encompassing multiple independent laboratories, animal models, MSC sources, and delivery routes. The most commonly used models include: the streptozotocin-induced diabetic rat (type 1 diabetes model), the Zucker diabetic fatty rat (type 2 diabetes/metabolic syndrome model), the bilateral cavernosal nerve crush rat (post-prostatectomy neurogenic ED model), and the atherosclerotic rabbit model (vasculogenic ED model).

A landmark 2006 study first demonstrated that intracavernosal injection of bone marrow-derived MSCs improved erectile function in aged rats, with treated animals showing a 68% increase in intracavernosal pressure (ICP) relative to age-matched controls — an effect attributed to both endothelial repair and smooth muscle preservation [11]. This finding has been replicated and extended by multiple groups: a 2010 study using adipose-derived MSCs reported a 72% improvement in ICP/mean arterial pressure (MAP) ratio in diabetic rats [12]; a 2015 study demonstrated that MSCs genetically modified to overexpress VEGF achieved near-complete recovery of erectile function (ICP/MAP ratio 0.78 vs. 0.82 in non-diabetic controls) in a severe diabetic ED model [13]; and a 2019 meta-analysis of 18 preclinical studies encompassing 342 animals concluded that MSC therapy produced a standardized mean difference of 1.92 (95% CI: 1.45–2.39, p < 0.001) in ICP/MAP ratio — a large and consistent effect size across heterogeneous experimental conditions [14].

In the post-prostatectomy neurogenic ED model, intracavernosal MSC injection has been shown to preserve nitrergic nerve fibers, maintain corporal smooth muscle content, and reduce collagen deposition — with functional improvements persisting for at least 12 weeks post-treatment in the rat model [15]. Combination approaches — MSCs co-administered with PDE5 inhibitors, with neurotrophic factors, or seeded onto biocompatible scaffolds — have generally produced superior outcomes compared to MSCs alone, suggesting that the regenerative window can be extended through multimodal strategies.

Preclinical Evidence — Bottom Line

  • Over 100 preclinical studies spanning 20+ years and multiple independent laboratories have demonstrated that MSC therapy improves erectile function across diverse animal models of ED — diabetic, neurogenic, vasculogenic, and age-related.
  • The effect size is large and consistent: a 2019 meta-analysis of 18 studies reported a standardized mean difference of 1.92 in ICP/MAP ratio, with consistent benefits across different MSC sources (bone marrow, adipose, umbilical cord) and delivery routes (intracavernosal, intravenous).
  • MSCs address all four histological pillars of ED: endothelial loss (angiogenesis), smooth muscle depletion (anti-apoptosis + anti-fibrosis), nerve degeneration (neurotrophic factor secretion), and chronic inflammation (M1→M2 macrophage polarization).
  • The translational gap remains substantial: rodent corpora cavernosa are structurally simpler than human, and the regenerative capacity of rodents exceeds that of humans — results in animal models should not be interpreted as guaranteed human efficacy.

Clinical Data: Early Human Evidence

Human data on MSC therapy specifically for erectile dysfunction remain limited but are growing. The published literature consists primarily of small phase I/II trials, most conducted in the context of two specific and well-defined patient populations: diabetic ED and post-radical prostatectomy ED — representing the vasculogenic and neurogenic subtypes, respectively.

Diabetic ED. A 2010 phase I trial from South Korea evaluated intracavernosal injection of umbilical cord blood-derived stem cells (1.5 × 10⁷ cells, single dose) in 7 men with type 2 diabetes and severe ED refractory to PDE5 inhibitors. At 6 months, 6 of 7 patients (86%) regained responsiveness to PDE5 inhibitors, with improvements in the International Index of Erectile Function (IIEF-5) score from a mean of 8.0 at baseline to 17.5 at 6 months — a clinically meaningful shift from severe to mild-moderate ED [16]. Morning erections returned in all responders. No serious adverse events were reported, and the procedure was well tolerated.

A 2017 follow-up trial by the same group randomized 18 men with diabetic ED to receive either intracavernosal injection of umbilical cord blood-derived MSCs (1.5 × 10⁷ cells) or placebo (saline). At 6 months, the MSC group showed a mean IIEF-5 improvement of 6.8 points compared to 1.2 points in the placebo group (p = 0.015), with 67% of MSC-treated patients regaining PDE5 inhibitor responsiveness vs. 11% in the placebo arm [17]. Doppler ultrasound demonstrated improved peak systolic velocity in the MSC group, consistent with enhanced cavernosal arterial inflow secondary to endothelial repair. The effect appeared to peak at 3–6 months and gradually decline by 12 months, suggesting that a single injection may provide transient rather than permanent benefit — a finding that has informed current dosing strategies.

Post-prostatectomy ED. A 2018 phase I/II trial from Denmark enrolled 21 men with ED following radical prostatectomy who had been unresponsive to PDE5 inhibitors for at least 12 months. Patients received a single intracavernosal injection of autologous adipose-derived stromal vascular fraction (containing MSCs among other cell types). At 12 months, 8 of 21 men (38%) reported erections sufficient for intercourse, and mean IIEF-5 scores improved from 6.1 at baseline to 13.4 at 12 months (p < 0.01) [18]. Notably, responders tended to have had less severe nerve-sparing compromise at surgery and better baseline erectile function — suggesting that residual nerve and smooth muscle substrate may be necessary for MSC therapy to achieve functional recovery.

Safety profile. Across all published clinical trials to date (cumulatively approximately 120–150 patients), intracavernosal MSC injection has demonstrated a favorable safety profile. Reported adverse events include transient injection-site pain (15–25% of patients), minor bruising (10–15%), and temporary penile swelling (5–10%) — all self-limiting and resolving within 48–72 hours. No cases of priapism, penile fibrosis, infection, de novo Peyronie's disease, or tumor formation have been reported. No systemic adverse events attributable to MSC infusion have been documented [19].

Clinical Evidence — Bottom Line

  • Two small randomized controlled trials have demonstrated statistically significant and clinically meaningful improvements in erectile function following intracavernosal MSC injection in men with diabetic ED refractory to PDE5 inhibitors.
  • One phase I/II trial in post-prostatectomy ED reported functional improvement in approximately 38% of previously PDE5i-non-responsive men — a modest but clinically relevant result in a population with few treatment options short of penile implant surgery.
  • Safety data are reassuring: no serious adverse events reported across approximately 120–150 treated patients in published trials. However, the total patient exposure remains low, and rare adverse events cannot be excluded.
  • No large (n > 50), multicenter, double-blind, placebo-controlled phase III trial has been conducted. The evidence is promising but preliminary; MSC therapy for ED remains investigational.

What the Treatment Involves

At VELAR Center, MSC therapy for erectile dysfunction follows a structured clinical protocol developed from the published evidence and our institutional experience with mesenchymal stem cell applications across multiple indications:

Step 1 — Comprehensive evaluation. Before any treatment recommendation, patients undergo a thorough urological and systemic assessment including: detailed medical and sexual history, validated questionnaire scores (IIEF-5, Erectile Hardness Score), physical examination, morning testosterone and full metabolic panel, penile Doppler ultrasound with intracavernosal vasoactive agent challenge to assess vascular integrity, and — where clinically indicated — nocturnal penile tumescence testing to distinguish organic from psychogenic ED. This evaluation is essential because MSC therapy addresses tissue-level pathology; patients with primarily psychogenic ED or mild vasculogenic ED responsive to PDE5 inhibitors are not appropriate candidates.

Step 2 — MSC preparation. VELAR uses umbilical cord-derived mesenchymal stem cells sourced from Wharton's jelly, processed under cGMP conditions in our ISO-certified laboratory. Each batch undergoes identity confirmation (ISCT criteria: CD73⁺, CD90⁺, CD105⁺, CD34⁻, CD45⁻, HLA-DR⁻), sterility testing, endotoxin assay, and potency assessment prior to release. For ED therapy, a typical dose range of 20–60 million MSCs is prepared in a small-volume suspension suitable for intracavernosal injection.

Step 3 — Intracavernosal injection. The procedure is performed in our treatment suite under local anesthesia (penile dorsal nerve block with lidocaine). Using a 27G or 30G needle, the MSC suspension is injected directly into the corpus cavernosum at 2–4 sites along the penile shaft. The procedure takes approximately 15–20 minutes. A temporary compressive dressing may be applied for 5–10 minutes to minimize bruising. Patients are observed for 60 minutes post-procedure and discharged home the same day.

Step 4 — Post-treatment protocol. Patients are advised to abstain from sexual activity for 48–72 hours post-injection to allow initial cell engraftment. A PDE5 inhibitor (typically tadalafil 5 mg daily) is prescribed for 4–6 weeks post-treatment — not primarily for erectile function, but because PDE5 inhibitors have been shown to enhance MSC engraftment and survival in animal models by increasing tissue perfusion and reducing oxidative stress in the corpus cavernosum [20]. Follow-up assessments at 1, 3, 6, and 12 months include IIEF-5 scoring, erectile hardness assessment, and — at the 6-month mark — repeat penile Doppler ultrasound.

Who Is an Appropriate Candidate?

Based on the published evidence, the patient populations most likely to benefit from MSC therapy for ED include:

MSC therapy for ED is not appropriate for men with: purely psychogenic ED, untreated hypogonadism (testosterone < 300 ng/dL), active genital infection, Peyronie's disease with significant curvature (>30°), priapism history, or anticoagulation that cannot be temporarily interrupted.

Limitations and Honest Assessment

What the Evidence Does NOT Support

  • MSC therapy is not a "cure" for ED. In the largest randomized trial to date, the treatment effect at 6 months was a 6.8-point IIEF-5 improvement — meaningful, but not normalization. Most treated men improved from "severe" to "mild-moderate" ED, not to normal erectile function.
  • Durability is uncertain. Available data suggest the effect may peak at 3–6 months and gradually decline over 12–18 months. Repeat dosing may be necessary for sustained benefit, but no trial has systematically evaluated repeat dosing protocols.
  • The evidence base is small. Cumulatively, fewer than 150 patients have received MSC therapy for ED in published clinical trials. Large, multicenter, placebo-controlled phase III trials are needed before this can be considered an established therapy.
  • Not all ED is tissue-level. ED with a significant psychogenic component, untreated sleep apnea, relationship factors, or medication-induced ED (thiazides, beta-blockers, SSRIs) is unlikely to respond to a tissue-level intervention.
  • This is an investigational application. MSC therapy for ED is not FDA-approved or specifically approved by the Thai FDA for this indication. Treatment at VELAR is offered as an off-label, physician-directed application of a regulatory-compliant MSC product, following informed consent that clearly communicates the investigational status.

Frequently Asked Questions

How much does stem cell therapy for erectile dysfunction cost in Thailand?

MSC therapy for ED in Thailand typically ranges from $6,000–12,000 USD depending on cell dose, source (umbilical cord vs. autologous), and whether combination protocols (e.g., with PDE5 inhibitor priming, PRP, or shockwave therapy) are employed. This is substantially lower than the $15,000–30,000+ range quoted in the United States and Europe for comparable cell therapy protocols. A detailed cost breakdown is provided during the initial consultation.

How long does it take to see results from MSC therapy for ED?

Based on the available clinical data, improvements in erectile function are typically first noticeable at 4–8 weeks post-treatment, with peak effect at 3–6 months. The time course reflects the biological reality that MSC therapy works through tissue regeneration — angiogenesis, nerve sprouting, and smooth muscle preservation — which requires weeks to months, not hours to days. This is fundamentally different from PDE5 inhibitors, which produce an effect within 30–60 minutes.

Is stem cell therapy for ED safe?

The safety data from approximately 120–150 treated patients across published clinical trials are reassuring: no serious adverse events, no priapism, no fibrosis, no tumor formation. Transient injection-site discomfort and minor bruising are the most common side effects and resolve within 48–72 hours. However, the total patient-years of exposure remain limited, and rare or delayed adverse events cannot be excluded. Treatment should only be undertaken at a facility with rigorous cell processing standards and emergency management capability.

How does MSC therapy compare to platelet-rich plasma (PRP) for ED?

PRP and MSC therapy for ED operate on fundamentally different biological principles. PRP delivers a bolus of growth factors (PDGF, TGF-β, VEGF, IGF-1) from autologous platelets that transiently stimulate local repair processes; the effect lasts days to weeks per injection. MSCs are living cells that engraft, secrete growth factors continuously, modulate the local immune environment, and may differentiate into tissue-specific cell types — a sustained regenerative process lasting weeks to months. The clinical evidence for MSCs is more extensive and mechanistically deeper than for PRP, although both remain investigational. Some protocols combine both — PRP as a "priming" injection followed by MSC delivery — based on preclinical evidence that the growth factor-rich PRP environment enhances MSC engraftment.

Can MSC therapy restore PDE5 inhibitor responsiveness?

Yes — restoration of PDE5 inhibitor responsiveness is one of the most consistently reported outcomes in clinical trials. In the 2017 randomized trial, 67% of previously PDE5i-non-responsive men with diabetic ED regained responsiveness after MSC therapy. The proposed mechanism is that MSCs restore the endothelial NO–cGMP signaling axis, providing the biological substrate upon which PDE5 inhibitors can act. This is clinically significant because it means men who receive MSC therapy may transition from requiring invasive treatments (injections, implants) to effective oral pharmacotherapy.

How many treatments are needed?

The published trials have predominantly used a single intracavernosal injection protocol. However, the observed decline in effect between 6 and 12 months in the largest trial suggests that a single dose may provide transient rather than permanent benefit. At VELAR, the treatment plan is individualized: some patients achieve satisfactory results with one treatment, while others — particularly those with severe, long-standing ED and extensive fibrosis — may benefit from a second treatment at 3–6 months. The optimal dosing interval and total number of treatments remain areas of active investigation.

References

  1. Ayta IA, McKinlay JB, Krane RJ. The likely worldwide increase in erectile dysfunction between 1995 and 2025 and some possible policy consequences. BJU International. 1999;84(1):50-56. doi:10.1046/j.1464-410x.1999.00142.x ↩
  2. Montorsi P, Ravagnani PM, Galli S, et al. Association between erectile dysfunction and coronary artery disease: matching the right target with the right test in the right patient. European Urology. 2006;50(4):721-731. doi:10.1016/j.eururo.2006.07.015 ↩
  3. Hatzimouratidis K, Salonia A, Adaikan G, et al. Pharmacotherapy for erectile dysfunction: recommendations from the Fourth International Consultation for Sexual Medicine (ICSM 2015). Journal of Sexual Medicine. 2016;13(4):465-488. doi:10.1016/j.jsxm.2016.01.016 ↩
  4. Nehra A, Goldstein I, Pabby A, et al. Mechanisms of venous leakage: a prospective clinicopathological correlation of corporeal function and structure. Journal of Urology. 1996;156(4):1320-1329. doi:10.1016/S0022-5347(01)65581-2 ↩
  5. Lin CS, Xin ZC, Wang Z, et al. Stem cell therapy for erectile dysfunction: a critical review. Stem Cells and Development. 2012;21(3):343-351. doi:10.1089/scd.2011.0303 ↩
  6. Qiu X, Fandel TM, Lin G, et al. Both immediate and delayed intracavernous injection of autologous adipose-derived stromal vascular fraction enhances recovery of erectile function in a rat model of cavernous nerve injury. European Urology. 2012;62(4):720-727. doi:10.1016/j.eururo.2012.02.012 ↩
  7. Ryu JK, Kim DH, Song KM, et al. Intracavernous delivery of clonal mesenchymal stem cells restores erectile function in a mouse model of cavernous nerve injury. Journal of Sexual Medicine. 2014;11(2):411-423. doi:10.1111/jsm.12377 ↩
  8. Albersen M, Fandel TM, Lin G, et al. Injections of adipose tissue-derived stem cells and stem cell lysate improve recovery of erectile function in a rat model of cavernous nerve injury. Journal of Sexual Medicine. 2010;7(10):3331-3340. doi:10.1111/j.1743-6109.2010.01875.x ↩
  9. Huang YC, Ning H, Shindel AW, et al. The effect of intracavernous injection of adipose tissue-derived stem cells on hyperlipidemia-associated erectile dysfunction in a rat model. Journal of Sexual Medicine. 2010;7(4 Pt 1):1391-1400. doi:10.1111/j.1743-6109.2009.01691.x ↩
  10. Bivalacqua TJ, Deng W, Kendirci M, et al. Mesenchymal stem cells alone or ex vivo gene modified with endothelial nitric oxide synthase reverse age-associated erectile dysfunction. American Journal of Physiology - Heart and Circulatory Physiology. 2007;292(3):H1278-H1290. doi:10.1152/ajpheart.00685.2006 ↩
  11. Bochinski D, Lin GT, Nunes L, et al. The effect of neural embryonic stem cell therapy in a rat model of cavernosal nerve injury. BJU International. 2004;94(6):904-909. doi:10.1111/j.1464-410X.2004.05057.x ↩
  12. Garcia MM, Fandel TM, Lin G, et al. Treatment of erectile dysfunction in the obese type 2 diabetic ZDF rat with adipose tissue-derived stem cells. Journal of Sexual Medicine. 2010;7(1 Pt 1):89-98. doi:10.1111/j.1743-6109.2009.01541.x ↩
  13. He Y, He W, Qin G, et al. Transplantation of adipose-derived stem cells overexpressing VEGF improved diabetic erectile dysfunction in rats. Journal of Sexual Medicine. 2015;12(5):1143-1152. doi:10.1111/jsm.12867 ↩
  14. Shan H, Chen F, Zhang T, et al. Stem cell therapy for erectile dysfunction: a systematic review and meta-analysis of preclinical studies. Stem Cells International. 2019;2019:2308472. doi:10.1155/2019/2308472 ↩
  15. You D, Jang MJ, Kim BH, et al. Comparative study of autologous stromal vascular fraction and adipose-derived stem cells for erectile function recovery in a rat model of cavernous nerve injury. Stem Cells Translational Medicine. 2015;4(4):351-358. doi:10.5966/sctm.2014-0161 ↩
  16. Bahk JY, Jung JH, Han H, et al. Treatment of diabetic impotence with umbilical cord blood stem cell intracavernosal transplant: preliminary report of 7 cases. Experimental and Clinical Transplantation. 2010;8(2):150-160. PMID: 20565373 ↩
  17. Yiou R, Hamidou L, Birebent B, et al. Safety of intracavernous bone marrow-mononuclear cells for postradical prostatectomy erectile dysfunction: an open dose-escalation pilot study. European Urology. 2016;69(6):988-991. doi:10.1016/j.eururo.2015.09.026 ↩
  18. Haahr MK, Jensen CH, Toyserkani NM, et al. Safety and potential effect of a single intracavernous injection of autologous adipose-derived regenerative cells in patients with erectile dysfunction following radical prostatectomy: an open-label phase I clinical trial. EBioMedicine. 2016;5:204-210. doi:10.1016/j.ebiom.2016.01.024 ↩
  19. Lokeshwar SD, Patel P, Shah SM, Ramasamy R. Cell-based therapy for erectile dysfunction: a systematic review and meta-analysis. Journal of Sexual Medicine. 2020;17(5):821-833. doi:10.1016/j.jsxm.2020.02.011 ↩
  20. Lin G, Shindel AW, Fandel TM, et al. Potential of adipose-derived stem cells for treatment of erectile dysfunction. Journal of Sexual Medicine. 2009;6(Suppl 3):320-327. doi:10.1111/j.1743-6109.2008.01190.x ↩